184 related articles for article (PubMed ID: 30442335)
1. Effects of rapamycin on the mechanistic target of rapamycin (mTOR) pathway and telomerase in breast cancer cells.
Gopalakrishnan K; Venkatesan S; Low ESH; Hande MP
Mutat Res Genet Toxicol Environ Mutagen; 2018 Dec; 836(Pt B):103-113. PubMed ID: 30442335
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity.
deGraffenried LA; Friedrichs WE; Russell DH; Donzis EJ; Middleton AK; Silva JM; Roth RA; Hidalgo M
Clin Cancer Res; 2004 Dec; 10(23):8059-67. PubMed ID: 15585641
[TBL] [Abstract][Full Text] [Related]
3. Rapamycin inhibits hTERT telomerase mRNA expression, independent of cell cycle arrest.
Bae-Jump VL; Zhou C; Gehrig PA; Whang YE; Boggess JF
Gynecol Oncol; 2006 Mar; 100(3):487-94. PubMed ID: 16249016
[TBL] [Abstract][Full Text] [Related]
4. Rapamycin inhibits telomerase activity by decreasing the hTERT mRNA level in endometrial cancer cells.
Zhou C; Gehrig PA; Whang YE; Boggess JF
Mol Cancer Ther; 2003 Aug; 2(8):789-95. PubMed ID: 12939469
[TBL] [Abstract][Full Text] [Related]
5. Compensatory Increase of Transglutaminase 2 Is Responsible for Resistance to mTOR Inhibitor Treatment.
Cao J; Huang W
PLoS One; 2016; 11(2):e0149388. PubMed ID: 26872016
[TBL] [Abstract][Full Text] [Related]
6. Mammalian target of rapamycin: a new molecular target for breast cancer.
Mita MM; Mita A; Rowinsky EK
Clin Breast Cancer; 2003 Jun; 4(2):126-37. PubMed ID: 12864941
[TBL] [Abstract][Full Text] [Related]
7. The investigational Aurora kinase A inhibitor alisertib (MLN8237) induces cell cycle G2/M arrest, apoptosis, and autophagy via p38 MAPK and Akt/mTOR signaling pathways in human breast cancer cells.
Li JP; Yang YX; Liu QL; Pan ST; He ZX; Zhang X; Yang T; Chen XW; Wang D; Qiu JX; Zhou SF
Drug Des Devel Ther; 2015; 9():1627-52. PubMed ID: 25834401
[TBL] [Abstract][Full Text] [Related]
8. The isoprenoid perillyl alcohol inhibits telomerase activity in prostate cancer cells.
Sundin T; Peffley DM; Gauthier D; Hentosh P
Biochimie; 2012 Dec; 94(12):2639-48. PubMed ID: 22902867
[TBL] [Abstract][Full Text] [Related]
9. The antitumor effect of GDC-0941 alone and in combination with rapamycin in breast cancer cells.
Zheng J; Zou X; Yao J
Chemotherapy; 2012; 58(4):273-81. PubMed ID: 23006739
[TBL] [Abstract][Full Text] [Related]
10. mTOR, a novel target in breast cancer: the effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer.
Yu K; Toral-Barza L; Discafani C; Zhang WG; Skotnicki J; Frost P; Gibbons JJ
Endocr Relat Cancer; 2001 Sep; 8(3):249-58. PubMed ID: 11566616
[TBL] [Abstract][Full Text] [Related]
11. IL-2 increases human telomerase reverse transcriptase activity transcriptionally and posttranslationally through phosphatidylinositol 3'-kinase/Akt, heat shock protein 90, and mammalian target of rapamycin in transformed NK cells.
Kawauchi K; Ihjima K; Yamada O
J Immunol; 2005 May; 174(9):5261-9. PubMed ID: 15843522
[TBL] [Abstract][Full Text] [Related]
12. New targets for therapy in breast cancer: mammalian target of rapamycin (mTOR) antagonists.
Carraway H; Hidalgo M
Breast Cancer Res; 2004; 6(5):219-24. PubMed ID: 15318929
[TBL] [Abstract][Full Text] [Related]
13. Disruption of an hTERT-mTOR-RAPTOR protein complex by a phytochemical perillyl alcohol and rapamycin.
Sundin T; Peffley DM; Hentosh P
Mol Cell Biochem; 2013 Mar; 375(1-2):97-104. PubMed ID: 23283642
[TBL] [Abstract][Full Text] [Related]
14. Activation of the Akt/mammalian target of rapamycin/4E-BP1 pathway by ErbB2 overexpression predicts tumor progression in breast cancers.
Zhou X; Tan M; Stone Hawthorne V; Klos KS; Lan KH; Yang Y; Yang W; Smith TL; Shi D; Yu D
Clin Cancer Res; 2004 Oct; 10(20):6779-88. PubMed ID: 15501954
[TBL] [Abstract][Full Text] [Related]
15. Role of glycogen synthase kinase 3beta in rapamycin-mediated cell cycle regulation and chemosensitivity.
Dong J; Peng J; Zhang H; Mondesire WH; Jian W; Mills GB; Hung MC; Meric-Bernstam F
Cancer Res; 2005 Mar; 65(5):1961-72. PubMed ID: 15753396
[TBL] [Abstract][Full Text] [Related]
16. Mammalian target of rapamycin inhibitors rapamycin and RAD001 (everolimus) induce anti-proliferative effects in GH-secreting pituitary tumor cells in vitro.
Gorshtein A; Rubinfeld H; Kendler E; Theodoropoulou M; Cerovac V; Stalla GK; Cohen ZR; Hadani M; Shimon I
Endocr Relat Cancer; 2009 Sep; 16(3):1017-27. PubMed ID: 19509067
[TBL] [Abstract][Full Text] [Related]
17. Rapamycin provides a therapeutic option through inhibition of mTOR signaling in chronic myelogenous leukemia.
Li J; Xue L; Hao H; Han Y; Yang J; Luo J
Oncol Rep; 2012 Feb; 27(2):461-6. PubMed ID: 21993902
[TBL] [Abstract][Full Text] [Related]
18. Anticancer effect of rapamycin on MCF-7 via downregulation of VEGF expression.
Fujii T; Yajima R; Tatsuki H; Oosone K; Kuwano H
In Vitro Cell Dev Biol Anim; 2016 Jan; 52(1):45-8. PubMed ID: 26427711
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of mTOR sensitizes breast cancer stem cells to radiation-induced repression of self-renewal through the regulation of MnSOD and Akt.
Lai Y; Yu X; Lin X; He S
Int J Mol Med; 2016 Feb; 37(2):369-77. PubMed ID: 26707081
[TBL] [Abstract][Full Text] [Related]
20. A novel autosomal recessive TERT T1129P mutation in a dyskeratosis congenita family leads to cellular senescence and loss of CD34+ hematopoietic stem cells not reversible by mTOR-inhibition.
Stockklausner C; Raffel S; Klermund J; Bandapalli OR; Beier F; Brümmendorf TH; Bürger F; Sauer SW; Hoffmann GF; Lorenz H; Tagliaferri L; Nowak D; Hofmann WK; Buergermeister R; Kerber C; Rausch T; Korbel JO; Luke B; Trumpp A; Kulozik AE
Aging (Albany NY); 2015 Nov; 7(11):911-27. PubMed ID: 26546739
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
